Sign inCreate account

Report workspace

Add to folder
NCT02960646COMPLETEDanonymous

Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation

Sponsor

Source record

M.D. Anderson Cancer Center

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Engineered T cells from haploidentical donors aimed at reducing graft-versus-host disease (GVHD) in hematologic malignancies.

Indication / condition

AI-normalized

Acute Lymphoblastic Leukemia

Intervention

Source record

Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus, Total-Body Irradiation

Source & freshness

Source record

NCT ID

NCT02960646

Original source

ClinicalTrials.gov

Source last updated

Feb 16, 2023

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02960646

Title

Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation

Sponsor

M.D. Anderson Cancer Center

Status

COMPLETED

Phase

Phase 1

Condition raw

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome

Condition normalized

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Engineered T cells from haploidentical donors aimed at reducing graft-versus-host disease (GVHD) in hematologic malignancies.

Target normalized

Engineered T cells from haploidentical donors aimed at reducing graft-versus-host disease (GVHD) in hematologic malignancies.

Interventions

Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus, Total-Body Irradiation

Public preview

Source record

The Phase I trial conducted by M.D. Anderson Cancer Center explores the safety and efficacy of an engineered peripheral blood graft for haploidentical transplantation in patients with high-risk hematologic malignancies. Given the increasing incidence of hematologic cancers and the limitations of current transplant options, this study addresses a significant unmet medical need. The results could position the sponsor favorably in the competitive landscape of stem cell transplantation, particularly against established therapies. The collaboration with the National Cancer Institute (NCI) may enhance credibility and facilitate future funding opportunities. Market implications include potential licensing agreements or partnerships if the trial demonstrates favorable outcomes, particularly in reducing GVHD, which remains a major complication in transplant procedures.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT02960646

Status

COMPLETED

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Executive brief

Investment-Ready Snapshot

The Phase I trial conducted by M.D. Anderson Cancer Center explores the safety and efficacy of an engineered peripheral blood graft for haploidentical transplantation in patients with high-risk hematologic malignancies. Given the increasing incidence of hematologic cancers and the limitations of current transplant options, this study addresses a significant unmet medical need. The results could position the sponsor favorably in the competitive landscape of stem cell transplantation, particularly against established therapies. The collaboration with the National Cancer Institute (NCI) may enhance credibility and facilitate future funding opportunities. Market implications include potential licensing agreements or partnerships if the trial demonstrates favorable outcomes, particularly in reducing GVHD, which remains a major complication in transplant procedures.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 16, 2023
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02960646

Indication

Acute Lymphoblastic Leukemia

Modality

small molecule

Target

Engineered T cells from haploidentical donors aimed at reducing graft-versus-host disease (GVHD) in hematologic malignancies.

Intervention

Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus, Total-Body Irradiation

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.